ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
펩티드 약물 복합체 시장 규모는 향후 몇 년 동안 급속한 성장을 보일 것으로 예상됩니다. 예측 기간 동안의 성장은 전 세계적으로 암 발병률의 증가, 표적 암 치료에 대한 수요 증가, 펩타이드 기반 약물 후보의 파이프라인 확대, 개인 맞춤형 의학의 확대, 복합 치료에 대한 관심 증가와 같은 요인에 기인할 수 있습니다. 예측 기간에 영향을 미칠 것으로 예상되는 주요 동향으로는 펩타이드 합성 기술의 개선, 링커 기술의 발전, 부위별 접합 방법의 개선, 종양 표적화 능력의 향상, 페이로드 선택의 혁신 등이 있습니다.
개인 맞춤형 치료에 대한 수요가 증가함에 따라 향후 몇 년 동안 펩티드 약물 복합체 시장이 성장할 것으로 예상됩니다. 개인 맞춤형 치료는 가장 효과적인 결과를 얻기 위해 개인의 고유한 유전적 구성, 생활 방식 및 질병 특성에 맞춘 치료법입니다. 이러한 증가는 특정 질병 마커를 식별하여 보다 정확하고 효과적인 치료를 가능하게 하는 유전체학의 발전에 의해 촉진되고 있습니다. 펩티드 약물 복합체의 경우, 개인 맞춤형 치료는 환자의 고유한 질병 바이오마커를 표적으로 하는 특정 펩티드를 선택할 수 있게 하여, 보다 정확하고 효과적인 약물 전달을 보장합니다. 예를 들어, 2024년 2월, Personalized Medicine Coalition은 FDA가 2023년에 희귀 질환 환자를 위한 16개의 새로운 맞춤형 의약품을 승인했다고 보고했습니다. 이는 2022년에 승인된 6개에 비해 크게 증가한 수치입니다. 그 결과, 개인 맞춤형 치료에 대한 수요가 증가하면서 펩티드 약물 복합체 시장의 성장이 가속화될 것으로 보입니다.
펩티드 약물 복합체 시장의 선도 기업들은 치료의 정확성을 높이기 위해 종양 선택적 펩티드 약물 복합체와 같은 첨단 치료 옵션을 개발하는 데 집중하고 있습니다. 이러한 치료법은 암세포에 결합하도록 특별히 설계된 펩티드를 사용하여 종양에 세포 독성 물질을 직접 전달하는 동시에 건강한 조직에 대한 손상을 최소화합니다. 예를 들어, 2025년 3월, 미국에 본사를 둔 종양학 생명공학 기업인 Cybrexa Therapeutics는 자사의 알파렉스 기술에 대한 새로운 전임상 데이터를 공개했습니다. 이 데이터는 Cybrexa의 항원 무관 펩티드-약물 복합체(PDC) 플랫폼이 강력한 미세소관 억제제를 종양 세포에 직접 전달하는 데 효과적이라는 점을 강조했습니다. 이 접근법은 종양 성장을 억제할 뿐만 아니라 지속적인 항종양 면역 반응을 유발합니다. 이 결과는 Cybrexa의 기술이 암 치료를 발전시키는 데 잠재력을 지니고 있음을 강조합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 19 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 펩티드 약물 복합체 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 펩티드 약물 복합체 시장 : 성장률 분석
세계의 펩티드 약물 복합체 시장 실적 : 규모와 성장(2019-2024년)
세계 펩티드 약물 복합체 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 펩티드 약물 복합체 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 펩티드 약물 복합체 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
치료
진단
세계의 펩티드 약물 복합체 시장 : 치료 영역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
종양학
면역학
감염증
기타 치료 분야
세계의 펩티드 약물 복합체 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
정맥내
피하
기타 투여 경로
세계 펩티드 약물 복합체 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
클리닉
약국
기타 최종 사용자
세계의 펩티드 약물 복합체 시장, 치료별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
단일클론항체(mAbs)
세포 독성제
면역 조절제
표적 요법
세계의 펩티드 약물 복합체 시장, 진단별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
조영제
바이오마커 표적제
진단 키트
제7장 지역별, 국가별 분석
세계의 펩티드 약물 복합체 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 펩티드 약물 복합체 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
펩티드 약물 복합체 시장 : 경쟁 구도
펩티드 약물 복합체 시장 : 기업 프로파일
AstraZeneca PLC : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
BioNTech SE : 개요, 제품 및 서비스, 전략 및 재무 분석
Curium US LLC : 개요, 제품 및 서비스, 전략 및 재무 분석
ADC Therapeutics SA : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
PeptiDream Incorporated
PepGen Corporation
Theratechnologies Inc.
Italfarmaco Societa per Azioni
Protagonist Therapeutics Inc.
Alteogen Inc.
Metsera Inc.
Zealand Pharma A/S
Apellis Pharmaceuticals Inc.
Angiochem Inc.
Cybrexa Therapeutics Inc.
Ambrx Inc.
Oncopeptides Aktiebolag(AB)
ProteinQure Incorporated
Soricimed Biopharma Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
펩티드 약물 복합체 시장(2029년) : 새로운 기회를 제공하는 국가
펩티드 약물 복합체 시장(2029년) : 새로운 기회를 제공하는 부문
펩티드 약물 복합체 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
HBR
영문 목차
영문목차
Peptide drug conjugates (PDCs) are targeted treatments that combine peptides with cytotoxic drugs to enhance therapeutic precision. The peptide, which specifically binds to cell receptors, is conjugated with the drug, allowing it to target diseased cells, such as tumors, directly. This method improves the drug's stability, selectivity, and bioavailability, thereby boosting its therapeutic effectiveness while minimizing harm to healthy tissues.
The main types of peptide drug conjugates include therapeutic and diagnostic. A therapeutic peptide drug conjugate involves attaching a peptide to a drug, typically a cytotoxic agent, to target cancer cells or other diseased tissue directly. These PDCs are used in the treatment of oncology, immunology, infectious diseases, and more. They can be administered through various routes, including intravenous and subcutaneous, and are commonly used in hospitals, clinics, pharmacies, and other healthcare settings.
The peptide drug conjugate market research report is one of a series of new reports from The Business Research Company that provides peptide drug conjugate market statistics, including peptide drug conjugate industry global market size, regional shares, competitors with a peptide drug conjugate market share, detailed peptide drug conjugate market segments, market trends and opportunities, and any further data you may need to thrive in the peptide drug conjugate industry. This peptide drug conjugate market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The peptide drug conjugates market size has grown rapidly in recent years. It will grow from $3.16 billion in 2024 to $3.68 billion in 2025 at a compound annual growth rate (CAGR) of 16.1%. The growth during the historic period can be attributed to several factors, including a favorable regulatory environment for biologics and peptides, an increase in orphan drug designations for peptide drugs, government incentives for rare disease treatments, the expanding biopharmaceutical sector, and rising global healthcare expenditure.
The peptide drug conjugates market size is expected to see rapid growth in the next few years. It will grow to $6.60 billion in 2029 at a compound annual growth rate (CAGR) of 15.8%. The growth during the forecast period can be attributed to factors such as the rising global prevalence of cancer, increasing demand for targeted cancer therapies, a growing pipeline of peptide-based drug candidates, the expansion of personalized medicine, and rising interest in combination therapies. Key trends expected to shape the forecast period include improvements in peptide synthesis techniques, advancements in linker technologies, enhanced site-specific conjugation methods, better tumor targeting capabilities, and innovations in payload selection.
The increasing demand for personalized treatments is expected to drive the growth of the peptide drug conjugates market in the coming years. Personalized treatments are therapies tailored to an individual's unique genetic makeup, lifestyle, and disease characteristics to achieve the most effective outcomes. This rise is driven by advancements in genomics, which help identify specific disease markers, enabling more precise and effective therapies. In the case of peptide drug conjugates, personalized treatments allow for the selection of specific peptides that target unique disease biomarkers in patients, ensuring more precise and effective drug delivery. For example, in February 2024, the Personalized Medicine Coalition reported that the FDA authorized 16 novel customized medicines for patients with rare disorders in 2023, a significant increase from the six authorized in 2022. As a result, the growing demand for personalized treatments is poised to accelerate the growth of the peptide drug conjugates market.
Leading companies in the peptide drug conjugates market are concentrating on developing advanced treatment options, such as tumor-selective peptide drug conjugates, to improve treatment precision. These therapies use peptides specifically engineered to bind to cancer cells, allowing for the direct delivery of cytotoxic agents to tumors while minimizing harm to healthy tissue. For example, in March 2025, Cybrexa Therapeutics, a US-based oncology biotechnology company, shared new preclinical data from its alphalex technology. The data highlighted the effectiveness of Cybrexa's antigen-agnostic peptide-drug conjugate (PDC) platform in delivering powerful microtubule inhibitors directly to tumor cells. This approach not only suppresses tumor growth but also triggers a lasting anti-tumor immune response. The findings underscore the potential of Cybrexa's technology in advancing cancer treatment.
In May 2023, Bayer AG, a Germany-based pharmaceutical company, entered into a strategic collaboration with Bicycle Therapeutics to develop novel radioconjugates targeting various oncology indications. Through this partnership, Bicycle Therapeutics will leverage its proprietary phage display platform to identify and optimize highly selective bicyclic peptides. Bayer will lead the preclinical and clinical development, as well as oversee manufacturing and commercialization efforts. The goal is to create targeted radiotherapy solutions that address critical gaps in cancer treatment. Bicycle Therapeutics is a UK-based company specializing in the development of peptide drug conjugates designed for precision oncology applications.
Major players in the peptide drug conjugates market are AstraZeneca PLC, Novartis AG, BioNTech SE, Curium US LLC, ADC Therapeutics SA, PeptiDream Incorporated, PepGen Corporation, Theratechnologies Inc., Italfarmaco Societa per Azioni, Protagonist Therapeutics Inc., Alteogen Inc., Metsera Inc., Zealand Pharma A/S, Apellis Pharmaceuticals Inc., Angiochem Inc., Cybrexa Therapeutics Inc., Ambrx Inc., Oncopeptides Aktiebolag (AB), ProteinQure Incorporated, Soricimed Biopharma Inc., Esperance Pharmaceuticals Inc., Adcytherix SA, and Araris Biotech AG.
North America was the largest region in the peptide drug conjugates market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in peptide drug conjugates report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the peptide drug conjugates market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The peptide drug conjugates market consists of revenues earned by entities by providing services such as conjugation services, preclinical testing, formulation development, target discovery, and validation. The market value includes the value of related goods sold by the service provider or included within the service offering. The peptide drug conjugates market also includes sales of peptide payload linkers, synthetic peptides, peptide targeting ligands, and drug delivery systems. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Peptide Drug Conjugates Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on peptide drug conjugates market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for peptide drug conjugates ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The peptide drug conjugates market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Therapeutic; Diagnostic
2) By Therapy Area: Oncology; Immunology; Infectious Diseases; Other Therapy Areas
3) By Route of Administration: Intravenous; Subcutaneous; Other Routes Of Administration
4) By End User: Hospitals; Clinics; Pharmacies; Other End Users
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Peptide Drug Conjugates Market Characteristics
3. Peptide Drug Conjugates Market Trends And Strategies
4. Peptide Drug Conjugates Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Peptide Drug Conjugates Growth Analysis And Strategic Analysis Framework
5.1. Global Peptide Drug Conjugates PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Peptide Drug Conjugates Market Growth Rate Analysis
5.4. Global Peptide Drug Conjugates Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Peptide Drug Conjugates Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Peptide Drug Conjugates Total Addressable Market (TAM)
6. Peptide Drug Conjugates Market Segmentation
6.1. Global Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Therapeutic
Diagnostic
6.2. Global Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oncology
Immunology
Infectious Diseases
Other Therapy Areas
6.3. Global Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intravenous
Subcutaneous
Other Routes Of Administration
6.4. Global Peptide Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Pharmacies
Other End Users
6.5. Global Peptide Drug Conjugates Market, Sub-Segmentation Of Therapeutic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibodies (mAbs)
Cytotoxic Agents
Immunomodulatory Agents
Targeted Therapies
6.6. Global Peptide Drug Conjugates Market, Sub-Segmentation Of Diagnostic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Imaging Agents
Biomarker Targeting Agents
Diagnostic Kits
7. Peptide Drug Conjugates Market Regional And Country Analysis
7.1. Global Peptide Drug Conjugates Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Peptide Drug Conjugates Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Peptide Drug Conjugates Market
8.1. Asia-Pacific Peptide Drug Conjugates Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Peptide Drug Conjugates Market
9.1. China Peptide Drug Conjugates Market Overview
9.2. China Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Peptide Drug Conjugates Market
10.1. India Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Peptide Drug Conjugates Market
11.1. Japan Peptide Drug Conjugates Market Overview
11.2. Japan Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Peptide Drug Conjugates Market
12.1. Australia Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Peptide Drug Conjugates Market
13.1. Indonesia Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Peptide Drug Conjugates Market
14.1. South Korea Peptide Drug Conjugates Market Overview
14.2. South Korea Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Peptide Drug Conjugates Market
15.1. Western Europe Peptide Drug Conjugates Market Overview
15.2. Western Europe Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Peptide Drug Conjugates Market
16.1. UK Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Peptide Drug Conjugates Market
17.1. Germany Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Peptide Drug Conjugates Market
18.1. France Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Peptide Drug Conjugates Market
19.1. Italy Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Peptide Drug Conjugates Market
20.1. Spain Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Peptide Drug Conjugates Market
21.1. Eastern Europe Peptide Drug Conjugates Market Overview
21.2. Eastern Europe Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Peptide Drug Conjugates Market
22.1. Russia Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Peptide Drug Conjugates Market
23.1. North America Peptide Drug Conjugates Market Overview
23.2. North America Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Peptide Drug Conjugates Market
24.1. USA Peptide Drug Conjugates Market Overview
24.2. USA Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Peptide Drug Conjugates Market
25.1. Canada Peptide Drug Conjugates Market Overview
25.2. Canada Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Peptide Drug Conjugates Market
26.1. South America Peptide Drug Conjugates Market Overview
26.2. South America Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Peptide Drug Conjugates Market
27.1. Brazil Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Peptide Drug Conjugates Market
28.1. Middle East Peptide Drug Conjugates Market Overview
28.2. Middle East Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Peptide Drug Conjugates Market
29.1. Africa Peptide Drug Conjugates Market Overview
29.2. Africa Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Peptide Drug Conjugates Market Competitive Landscape And Company Profiles
30.1. Peptide Drug Conjugates Market Competitive Landscape
30.2. Peptide Drug Conjugates Market Company Profiles
30.2.1. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
30.2.3. BioNTech SE Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Curium US LLC Overview, Products and Services, Strategy and Financial Analysis
30.2.5. ADC Therapeutics SA Overview, Products and Services, Strategy and Financial Analysis
31. Peptide Drug Conjugates Market Other Major And Innovative Companies
31.1. PeptiDream Incorporated
31.2. PepGen Corporation
31.3. Theratechnologies Inc.
31.4. Italfarmaco Societa per Azioni
31.5. Protagonist Therapeutics Inc.
31.6. Alteogen Inc.
31.7. Metsera Inc.
31.8. Zealand Pharma A/S
31.9. Apellis Pharmaceuticals Inc.
31.10. Angiochem Inc.
31.11. Cybrexa Therapeutics Inc.
31.12. Ambrx Inc.
31.13. Oncopeptides Aktiebolag (AB)
31.14. ProteinQure Incorporated
31.15. Soricimed Biopharma Inc.
32. Global Peptide Drug Conjugates Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Peptide Drug Conjugates Market
34. Recent Developments In The Peptide Drug Conjugates Market
35. Peptide Drug Conjugates Market High Potential Countries, Segments and Strategies
35.1 Peptide Drug Conjugates Market In 2029 - Countries Offering Most New Opportunities
35.2 Peptide Drug Conjugates Market In 2029 - Segments Offering Most New Opportunities
35.3 Peptide Drug Conjugates Market In 2029 - Growth Strategies
